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SUMMARY The aim of the study was to assess the prevalence of contact 
allergy to glucocorticosteroids in patients with chronic venous leg ulcers 
(CVLU), atopic dermatitis (AD) and contact dermatitis (CD), and in a group of 
healthy individuals; and to estimate differences among these patient groups. 
Patch tests with the European standard series, antibiotics, glucocorticosteroid 
contact allergy screening markers and ointment vehicles were performed in a 
population of 140 patients. Positive patch tests results were recorded in 80% 
and contact allergy to glucocorticosteroids in 40% of CVLU patients. In the 
group of AD patients, the respective figures were 30% and 3%. In the group 
of CD patients, allergic type of disease was detected in 80% and positive 
patch tests for glucocorticosteroids in 20% of patients. In healthy individuals, 
allergic contact reaction was observed in 17% of cases. Statistically significant 
differences among patient groups were found according to the prevalence of 
contact allergy, polyvalent allergy and contact allergy to glucocorticosteroids. 
We suggest that glucocorticosteroid contact allergy should be considered as 
a crucial clinical problem in patients with inflammatory dermatoses like CVLU, 
AD and CD. 
KeY woRdS: contact allergy, glucocorticosteroids, venous leg ulcers, atopic 
dermatitis, contact dermatitis
INTRodUCTIoN
Contact allergy to topical glucocorticosteroids 
has been recognized as a problem of both clini-
cal and therapeutic importance. It affects 0.5% to 
5.8% of patients (1-4). The prevalence of contact 
allergy to these agents depends mainly on the type 
of dermatosis investigated, type of glucocortico-
steroid screening markers used on patch testing 
and awareness of glucocorticosteroid contact al-
lergy, thus resulting in variable data reported in the 
literature (1,4). Among the risk factors for develop-
ing delayed type of hypersensitivity to topical cor-
ticosteroids, chronic inflammatory skin diseases 
and patients presenting two or more positive patch 
test results and multiple medicament sensitivities 
seem to be most important (5,6). Patients suffer-
ing from chronic venous leg ulcers (CVLU), stasis 
dermatitis and contact dermatitis (CD) are also 
known as an increased risk group (2,7,8). Contact 
allergy in patients with atopic dermatitis (AD) af-
fects up to 40% of cases, which has become an 
important clinical problem that may sometimes be 
difficult to recognize (9,10). AD patients seem to 
be a potential population for developing contact 
allergic reaction to glucocorticosteroids. Dooms-
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Gossens and Degreef suggest that each case of 
CD resistant to glucocorticosteroids topical treat-
ment should be considered as a hypersensitivity 
reaction to the medication applied (11). Moreover, 
according to observations reported from various 
clinical researches, the prevalence of contact al-
lergy to glucocorticosteroids tends to increase 
(2,12,13). Recently, there was a very interesting 
and detailed discussion concerning the method-
ology of diagnostic procedures (1-3,7,8,14-22). 
Corticosteroid screening markers include at least 
tixocortol pivalate and budesonide (for corticoste-
roid cross-reaction groups A, B and D). This panel 
might be completed by a group C marker such as 
betamethasone-17-valerate or hydrocortisone-
17-butyrate (1,2,18,22). Thomson et al. showed a 
combination of tixocortol pivalate and budesonide 
to detect more than 90% of contact allergy to 
steroids (8). Due to anti-inflammatory properties of 
corticosteroids, which may suppress allergic reac-
tion at early readings, it is recommended to perform 
the verifying late reading on day 7 (3,16,20,22). 
The aim of this study was to evaluate the preva-
lence of contact allergy to glucocorticosteroids in 
patients with CVLU, AD and CD, and in a group 
of healthy individuals as well as to estimate differ-
ences between the study groups of patients con-
sidering contact and polyvalent allergy and allergic 
contact reaction to the specific allergens applied.
MATeRIALS ANd MeTHodS
Fifty CVLU patients, 30 AD patients, 30 CD 
patients and 30 healthy individuals were enrolled 
in the study. Patients with diabetes mellitus, hy-
pertension and active stasis dermatitis or contact 
dermatitis were excluded from the study. In CVLU 
Table 1. List of allergens tested in study groups (number and percentage of positive reactions)







Potassium dichromate (0.5) 3 (6%) 3 (10%) 6 (20%) 1 (3%)
Neomycin sulfate (20) 10 (20%) 0 4 (13%) 0
Thiuram mix (1) 0 0 1 (3%) 0
Paraphenylenediamine (1) 2 (4%) 1 (3%) 1 (3%) 0
Cobalt chloride (1) 3 (6%) 1 (3%) 3 (10%) 1 (3%)
Benzocaine (5) 2 (4%) 0 0 1 (3%)
Formaldehyde aq (1) 0 0 1 (3%) 0
Colophony (20) 3 (6%) 1 (3%) 2 (7%) 0
Clioquinol (5) 5 (10%) 0 0 0
Balsam of Peru (25) 19 (38%) 1 (3%) 1 (3%) 0
N-Isopropyl-N-phenyl-4-phenylenediamine (0.1) 1 (2%) 0 1 (3%) 0
Wool alcohols (30) 15 (30%) 2 (7%) 0 0
Mercapto mix (2) 4 (8%) 0 1 (3%) 0
Epoxy resin (1) 1 (2%) 0 0 0
Paraben mix (16) 10 (20%) 1 (3%) 0 0
4-tetr-butylphenol formaldehyde resin (1) 3 (6%) 0 0 0
Fragrance mix (8) 10 (20%) 3 (10%) 4 (13%) 0
Quaternium-15 (1) 0 0 0 0
Nickel sulfate (5) 4 (8%) 2 (7%) 10 (33%) 2 (7%)
Kathon/Euxyl/Grotan (0.01) 0 0 0 0
Mercaptobenzothiazole (2) 1 (2%) 0 0 0
Sesquiterpenelactone mix (0.1) 0 0 0 0
Primin (0.01) 1 (2%) 0 0 0
Tixocortol pivalate (1) 8 (16%) 1 (3%) 3 (10%) 0
Budesonide (0.01) 10 (20%) 0 2 (7%) 0
Betamethasone-17-valerate (1) 2 (4%) 0 1 (3%) 0
Glucocorticosteroids: sum 16 (40%) 1 (3%) 6 (20%) 0
Gentamicin sulfate (20) 2 (4%) 0 1 (3%) 0
Lanolin (pure) 1 (2%) 0 0 0
Eucerin (pure) 1 (2%) 0 0 0
CVLU, chronic venous leg ulcers; AD, atopic dermatitis; CD, contact dermatitis
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group there were 38 (76%) female and 12 (24%) 
male patients, mean age 66.2 (range 48-81) years 
and mean duration of CVLU 7.2 years (range 6 
months to 35 years. In AD group there were 22 
(73%) female and 8 (27%) male patients, mean 
age 32.4 (range 18-58) years and mean duration 
of AD 16.8 (range 2-58) years. In CD group there 
were 22 (73%) female and 8 (27%) male patients, 
mean age 50.1 (range 24-71) years and mean du-
ration of CD 6.4 (range 1-21) years. In the group 
of healthy individuals there were 12 (40%) female 
and 18 (60%) male subjects, mean age 33.9 
(range 20-62) years. Clinical diagnosis of CVLU 
was verified by use of the clinical part of CEAP 
classification, color duplex ultrasound examination 
and ABPI (ankle brachial pressure index) determi-
nation. The diagnosis of AD was made according 
to Hanifin and Rajka criteria (23). 
Patch testing 
Patch tests were performed with the Europe-
an standard series (TROLAB, Hermal, Germany) 
supplemented with glucocorticosteroids (tixocortol 
pivalate, budesonide, betamethasone-17-valer-
ate), gentamicin (Chemotechnique Diagnostics, 
Sweden), and lanolin and eucerin as ointment ve-
hicles (Hospital Farmacy, Poland) (Table 1). For 
patch testing, Finn Chambers on Scanpor (Epit-
est, Finland) were used. Results were recorded at 
48 and 72 hour time points. For topical glucocorti-
costeroids the verifying readings were performed 
on day 7. According to ICDRG (International Con-
tact Dermatitis Research Group), reactions evalu-
ated as ++ and +++ were considered positive, and 
reactions evaluated as + as doubtful. Only ++ and 
+++ reactions were taken in consideration for fur-
ther analysis.   
ethics
The study was approved (opinion no. 503/02) 
by the Institutional Review Board, Poznan Univer-
sity of Medical Sciences. 
data analysis 
Comparative evaluations of the prevalence of 
contact and polyvalent allergy as well as the prev-
alence of positive allergic reactions to standard 
allergens and glucocorticosteroids in the study 
groups of patients were performed with Mann-
Whitney test and Fisher exact test. On statistical 
analysis, the STATISTICA version 6.0 and StatX-
act program version 4.0.1 were used.
ReSULTS
In the group of CVLU patients positive patch 
tests results were recorded in 80% of patients and 
polyvalent allergy in 56% of cases. In the group 
of AD patients following results were obtained: 
positive patch tests results in 30% and polyvalent 
allergy in 20% of patients. In the group of CD pa-
tients allergic type of CD was detected in 80% and 
polyvalent allergy in 33% of patients. In the group 
of healthy individuals allergic contact reaction was 
observed in 17% of cases. Positive patch test re-
sults in our groups of patients are characterized in 
Table 1 and frequencies of multiply positive reac-
tions (polyvalent allergies) are detailed in Table 2.
Contact and polyvalent allergy
The comparative evaluation of frequency of 
the contact and polyvalent allergy in our patients 
groups was performed. Considering contact al-
lergy frequency, the obtained difference was sta-
tistically significant between CVLU patients and 
both AD patients (p<0.0001) and healthy individu-
als (p=0). Moreover, statistically significant differ-
ence was found between CD patients and both 
AD patients and healthy individuals (accordingly 
p<0.001 and p<0.0001). Considering polyvalent 
allergy frequency, the obtained difference was 
statistically significant between CVLU patients 
and both AD patients (p<0.05) and healthy indi-
viduals (p=0). Moreover, statistically significant dif-
ference was found between both AD and CD pa-
tients and healthy individuals (accordingly p<0.05 
and p<0.001).
Table 2. Prevalence of polyvalent allergy in CVLU, 
AD and CD patients
Patient group
Number of positive 




















CVLU, chronic venous leg ulcers; AD, atopic dermatitis; 
CD, contact dermatitis
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Positive allergic reactions to standard aller-
gens and glucocorticosteroids
Comparative evaluation of positive allergic re-
actions frequency to standard allergens between 
examined groups of patients revealed statistically 
significant differences concerning the following al-
lergens: neomycin sulphate, balsam of Peru, wool 
alcohols, paraben mix and nickel sulfate (Table 
3). Comparisons of positive allergic reactions fre-
quency to glucocorticosteroids in examined groups 
of patients were evaluated. Statistically significant 
differences were found considering tixocortol piva-
late and budesonide (Table 4).
dISCUSSIoN
Contact allergy poses a problem in CVLU 
patients complicating the course of CVLU and 
making the disease difficult to diagnose. In many 
cases it is so because of a non-characteristic clini-
cal picture. Moreover, the chronic nature of the 
problem and the wide spectrum of the potential 
causative therapeutic agents and occlusive dress-
ings are factors that may favor both development 
of a delayed type of hypersensitivity and continu-
ous changes in the allergen pattern. Another very 
important problem recorded in our study was the 
very high prevalence of polyvalent allergic reac-
tions in CVLU patients. Our results confirmed 
those reported by other authors considering the 
high incidence of contact allergy and the role of 
the most common allergens in developing clinical 
symptoms of a delayed type of hypersensitivity in 
the study group of patients (24-27). Our study also 
demonstrated a very high incidence of contact 
allergy to glucocorticosteroids in CVLU patients 
(40%), which exceeded other literature reports 
(2,7,8,12,13,28). The use of tixocortol pivalate 
and budesonide combination and the verifying 
reading on day 7 enabled us to reduce the risk 
of omitting positive results. According to their al-
lergic potential, corticosteroids have been divided 
into four groups from A to D (subdivided into D1 
and D2 groups). Group A is known as the hydro-
cortisone type, group B as the triamcinolone ace-
tonide type, group C as the betamethasone type, 
group D1 as betamethasone dipropionate type 
and group D2 as methylprednisolone aceponate 
type (1,2,18,22). They appear to have a high po-
tential to cross-react within each group. However, 
cross-reactions between the groups are not com-
mon (22). We detected coexistence of positive 
results with tixocortol pivalate (group A represen-
tative) and budesonide (group B representative) 
in 3 (6%) cases and betamethasone-17-valerate 
(group D1 representative) with tixocortol pivalate 
or budesonide in 2 (4%) cases. The polyvalent 
glucocorticosteroid allergy in our group of CVLU 
patients was probably due to the chronic nature of 
venous insufficiency and leg ulcer processes as 
Table 3. Comparative evaluation of the prevalence of positive allergic reactions to standard allergens in 
study groups
Allergen Study groups compared p
Neomycin sulfate
CVLU patients/AD patients <0.05
CVLU patients/healthy individuals <0.05
Balsam of Peru
CVLU patients/AD patients <0.001
CVLU patients/CD patients <0.001
CVLU patients/healthy individuals <0.0001
Wool alcohols
CVLU patients/AD patients <0.05
CVLU patients/CD patients <0.001
CVLU patients/healthy individuals <0.001
Paraben mix 
CVLU patients/AD patients <0.05
CVLU patients/healthy individuals <0.05
Nickel sulfate
CD patients/CVLU patients <0.01
CD patients/AD patients <0.05
CD patients/healthy individuals <0.05
CVLU, chronic venous leg ulcers; AD, atopic dermatitis; CD, contact dermatitis
Table 4. Comparative evaluation of the prevalence 
of contact allergy to glucocorticosteroids in study 
populations










CVLU, chronic venous leg ulcers; AD, atopic dermatitis
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well as to the time of exposure to different cortico-
steroids used for stasis dermatitis. These observa-
tions confirmed justifiability of the use of tixocortol 
pivalate and budesonide as corticosteroid screen-
ing markers. On the other hand, the additional 
betamethasone-17-valerate positive reaction was 
an important practical observation determining the 
possible treatment options, especially in patients 
with chronic dermatoses. 
Allergic contact dermatitis in patients with AD 
affects up to 40% of cases, leading to an impor-
tant clinical problem that may be difficult to recog-
nize (9,10). The rate of 30% of positive patch tests 
results and the character of the most common 
contact allergens in our AD patients were quite 
similar to those reported elsewhere (24). Based 
on clinical trials, a group of risk factors for devel-
oping a delayed type of hypersensitivity to metals, 
especially nickel sulfate, in AD patients has been 
established, including female sex, young age and 
family or personal history of atopic diseases. In 
their epidemiological study, Mortz et al. detected a 
higher incidence of contact allergy in children with 
AD or bronchial asthma than in the group of con-
trol children without atopic diseases (29). More-
over, Berndt et al. emphasize the higher incidence 
of occupational contact dermatitis, especially to 
nickel sulfate, in adults with AD as compared with 
patients without this atopic skin disease (30). It is 
known that contact allergy to nickel sulfate may 
quite often coexist with allergy to other metals, 
especially cobalt chloride. The high prevalence of 
metal and fragrance allergens, common contact 
allergens as causative factors in AD patients, indi-
cates the risk of contact allergy development and 
thus therapeutic difficulties. Moreover, the definite 
possibility of developing occupational contact der-
matitis points to the necessity of proper patient 
education concerning the character of occupation 
chosen in young patients. Jappe et al. report on 
0.87% budesonide and 1.14% hydrocortisone-17-
butyrate positive patch test results in AD patients 
(10). Giordano-Labadie et al. did not observe 
contact allergy to glucocorticosteroids in any of 
their AD patients (9). Our study using both corti-
costeroid screening markers (tixocortol pivalate 
and budesonide) may offer another very important 
step in understanding the character of contact al-
lergy in AD patients. Another clinically important 
observation made on the basis of our results is 
that in our AD patients we detected a high inci-
dence of polyvalent allergy, which is a crucial fac-
tor for planning future topical treatment methods.
The prevalence of allergic contact reaction and 
contact allergy to the most common allergens re-
corded in CD patients is confirmed by literature 
data (30-34). Our results of contact allergy to glu-
cocorticosteroids showed a very high incidence in 
comparison to the results reported by Boffa et al. 
(5.98%) (3). Similar to CVLU patients, we detected 
no case of isolated allergic reaction to betametha-
sone-17-valerate, but here again the application of 
tixocortol pivalate and budesonide enabled us to 
detect more cases of glucocorticosteroid contact 
allergy. 
In the group of healthy individuals we obtained 
positive patch test results, mainly with metal al-
lergens (17%). This observation proves the high 
potency of metal allergens in provoking contact al-
lergy. Moreover, this can also be an evidence of 
“clinically mute” contact allergy, which in may sub-
sequently develop into the symptomatic picture of 
allergic contact dermatitis. 
Comparative evaluation of the prevalence of 
contact and polyvalent allergy as well as positive 
patch test results with both standard allergens and 
glucocorticosteroids revealed very interesting ob-
servations. CVLU patients should be classified as 
a group at the highest risk of developing contact 
allergy with the predominance of polyvalent al-
lergic reactions and, which is very important from 
the clinical standpoint, they form a group at the 
highest risk of developing contact allergy to glu-
cocorticosteroids. In AD patients, the problem of 
contact allergy and polyvalent allergy in some cas-
es seems to be very important while complicating 
both clinical picture and therapeutic options. Dif-
ferences between data on the prevalence of con-
tact hypersensitivity to several allergens are due 
to the characteristics of inflammatory diseases. 
Additional studies of the pathophysiology of aller-
gic contact reaction in CVLU patients as well as in 
AD patients are necessary and are planned to be 
performed at our Department of Dermatology and 
Allergic Diseases Diagnostic Center. 
In view of the above, on the basis of our clinical 
results, we would like to emphasize that contact 
allergy in the study groups of patients poses a ma-
jor problem, determining not only the course of the 
disease but also therapeutic possibilities and oc-
cupational implications. Moreover, we suggest that 
glucocorticosteroid contact allergy coexisting with 
the risk of cross-reactions between corticosteroid 
groups should be considered as a crucial clinical 
problem in patients with CVLU, AD and CD.
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